Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02400164 · ClinicalTrials.gov registry record · NA
A (M)Ulti-center, Prospective, (O)Pen Label, Uncontrolled Feasibility (S)Tudy to Assess the Safety and Effectiveness of an Automatic Low Flow (A)Scites (Alfa) Pump (I)n Patients With (C)Irrhosis and Refractory or Recurrent Ascites
A NA study of Cirrhosis and Ascites, sponsored by Sequana Medical N.V..
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 6
- Study locations
NCT02400164 is a NA study of Cirrhosis and Ascites that has completed, run by Sequana Medical N.V.. The registered enrollment target is 30 participants, below the 90,408-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT02400164, a NA study of Cirrhosis and Ascites, has completed, sponsored by Sequana Medical N.V..
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 6
- Study locations
Study Summary
The study is a multi-center, prospective, open label, uncontrolled feasibility study enrolling 30 patients with refractory or recurrent ascites and cirrhosis at up to 6 sites. Patients will be enrolled during a 6 month enrollment phase after which data will be collected for 12months with an initial analysis after 3 months. Extended follow-up for safety monitoring purposes will continue for the lifetime of the patient or until the device is explanted.
Interventions
- DEVICE alfapump system
Study Locations (6)
Virginia
- University of Virginia - Charlottesville
- VCU Medical Centre - Richmond
California
- California Pacific Medical - San Francisco
Minnesota
- Mayo Clinic - Rochester
Texas
- Baylor University Healthcare System - Dallas
Ontario
- Toronto General Hospital - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-03 |
| Est. Completion | 2018-03-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02400164
The ClinicalTrials.gov registry entry for NCT02400164 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90,408-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The listed sponsor is Sequana Medical N.V., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cirrhosis appearing as the primary indexed condition, and to 1 intervention - of which alfapump system is the first listed.
NCT02400164 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Virginia, California, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02400164 about?
NCT02400164 is a clinical study titled "A (M)Ulti-center, Prospective, (O)Pen Label, Uncontrolled Feasibility (S)Tudy to Assess the Safety and Effectiveness of an Automatic Low Flow (A)Scites (Alfa) Pump (I)n Patients With (C)Irrhosis and Refractory or Recurrent Ascites". The study is a multi-center, prospective, open label, uncontrolled feasibility study enrolling 30 patients with refractory or recurrent ascites and cirrhosis at up to 6 sites. Patients will be enrolled during a 6 month enrollment phase after which data will be collected for 12months with an initial ...
What is the current status of trial NCT02400164?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2015-03. Estimated completion is 2018-03-31.
What conditions does trial NCT02400164 study?
This clinical trial studies the following conditions: Cirrhosis, Ascites.
What interventions are being tested in trial NCT02400164?
The interventions under investigation include: alfapump system (DEVICE).
Who is sponsoring clinical trial NCT02400164?
This trial is sponsored by Sequana Medical N.V., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02400164 being conducted?
This trial has 6 study locations across California, Minnesota, Texas, Virginia, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
LiverSleep: A Behavioral Sleep Intervention for Patients With Cirrhosis and Insomnia
RECRUITING · NA
-
Copper Supplementation in Cirrhosis
RECRUITING · NA
-
HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease
RECRUITING · NA
-
CirrhosisRx CDS System
RECRUITING · NA
-
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
RECRUITING · NA
-
Microbiome Modulation With Prebiotics in PTSD and Cirrhosis
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.